- Home
- BATRK vs NKTR Comparison
BATRK vs NKTR Comparison
Compare BATRK & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BATRK | NKTR |
|---|---|---|
| Founded | 1991 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | BATRK | NKTR |
|---|---|---|
| Price | $43.39 | $70.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $57.00 | ★ $129.83 |
| AVG Volume (30 Days) | 335.3K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $307,711,000.00 |
| Revenue This Year | $12.40 | N/A |
| Revenue Next Year | $6.78 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $35.46 | $0.43 |
| 52 Week High | $47.16 | $75.67 |
Technical Indicators
Market Signals| Indicator | BATRK | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 63.28 | 66.81 |
| Support Level | $43.24 | $52.99 |
| Resistance Level | $45.61 | $75.67 |
| Average True Range (ATR) | 1.10 | 5.08 |
| MACD | 0.07 | -0.21 |
| Stochastic Oscillator | 66.99 | 67.04 |
Price Performance
Historical ComparisonAbout BATRK Atlanta Braves Holdings Inc. Series C
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.